Nonalcoholic fatty liver disease and the epidemic of obesity

Article Type
Changed
Mon, 10/08/2018 - 11:14
Display Headline
Nonalcoholic fatty liver disease and the epidemic of obesity
Article PDF
Author and Disclosure Information

Rochelle Collantes, MD, MPH
Research Associate, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Janus P. Ong, MD
Staff Hepatologist, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Zobair M. Younossi, MD, MPH
Director, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Address: Zobair M. Younossi, MD, MPH, Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042-3300

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

Issue
Cleveland Clinic Journal of Medicine - 71(8)
Publications
Topics
Page Number
657-664
Sections
Author and Disclosure Information

Rochelle Collantes, MD, MPH
Research Associate, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Janus P. Ong, MD
Staff Hepatologist, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Zobair M. Younossi, MD, MPH
Director, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Address: Zobair M. Younossi, MD, MPH, Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042-3300

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

Author and Disclosure Information

Rochelle Collantes, MD, MPH
Research Associate, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Janus P. Ong, MD
Staff Hepatologist, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Zobair M. Younossi, MD, MPH
Director, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Address: Zobair M. Younossi, MD, MPH, Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042-3300

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 71(8)
Issue
Cleveland Clinic Journal of Medicine - 71(8)
Page Number
657-664
Page Number
657-664
Publications
Publications
Topics
Article Type
Display Headline
Nonalcoholic fatty liver disease and the epidemic of obesity
Display Headline
Nonalcoholic fatty liver disease and the epidemic of obesity
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Cancer pain: How to measure the fifth vital sign

Article Type
Changed
Mon, 10/08/2018 - 10:18
Display Headline
Cancer pain: How to measure the fifth vital sign
Article PDF
Author and Disclosure Information

Mellar P. Davis, MD
Medical director, Harry R. Horvitz Center for Palliative Medicine, The Cleveland Clinic Foundation

Declan Walsh, MSc
The Harry R. Horvitz Chair in Palliative Medicine, The Cleveland Clinic Foundation

Address: Mellar P. Davis, MD, Harry R. Horvitz Center for Palliative Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail davism6@ccf.org

Issue
Cleveland Clinic Journal of Medicine - 71(8)
Publications
Topics
Page Number
625-632
Sections
Author and Disclosure Information

Mellar P. Davis, MD
Medical director, Harry R. Horvitz Center for Palliative Medicine, The Cleveland Clinic Foundation

Declan Walsh, MSc
The Harry R. Horvitz Chair in Palliative Medicine, The Cleveland Clinic Foundation

Address: Mellar P. Davis, MD, Harry R. Horvitz Center for Palliative Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail davism6@ccf.org

Author and Disclosure Information

Mellar P. Davis, MD
Medical director, Harry R. Horvitz Center for Palliative Medicine, The Cleveland Clinic Foundation

Declan Walsh, MSc
The Harry R. Horvitz Chair in Palliative Medicine, The Cleveland Clinic Foundation

Address: Mellar P. Davis, MD, Harry R. Horvitz Center for Palliative Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail davism6@ccf.org

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 71(8)
Issue
Cleveland Clinic Journal of Medicine - 71(8)
Page Number
625-632
Page Number
625-632
Publications
Publications
Topics
Article Type
Display Headline
Cancer pain: How to measure the fifth vital sign
Display Headline
Cancer pain: How to measure the fifth vital sign
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients

Article Type
Changed
Mon, 10/08/2018 - 10:14
Display Headline
Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients
Article PDF
Author and Disclosure Information

Kiran K. Khush, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco

David Waters, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco, and San Francisco General Hospital

Address: Kiran K. Khush, MD, Division of Cardiology, Department of Medicine, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143; e-mail kkhush@medicine.ucsf.edu

Dr. Waters has indicated that he is on the speakers’ bureau of Pfizer, Merck, and AstraZeneca, and has received grant or research support from AstraZeneca and Merck.

Issue
Cleveland Clinic Journal of Medicine - 71(8)
Publications
Topics
Page Number
609-616
Sections
Author and Disclosure Information

Kiran K. Khush, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco

David Waters, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco, and San Francisco General Hospital

Address: Kiran K. Khush, MD, Division of Cardiology, Department of Medicine, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143; e-mail kkhush@medicine.ucsf.edu

Dr. Waters has indicated that he is on the speakers’ bureau of Pfizer, Merck, and AstraZeneca, and has received grant or research support from AstraZeneca and Merck.

Author and Disclosure Information

Kiran K. Khush, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco

David Waters, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco, and San Francisco General Hospital

Address: Kiran K. Khush, MD, Division of Cardiology, Department of Medicine, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143; e-mail kkhush@medicine.ucsf.edu

Dr. Waters has indicated that he is on the speakers’ bureau of Pfizer, Merck, and AstraZeneca, and has received grant or research support from AstraZeneca and Merck.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 71(8)
Issue
Cleveland Clinic Journal of Medicine - 71(8)
Page Number
609-616
Page Number
609-616
Publications
Publications
Topics
Article Type
Display Headline
Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients
Display Headline
Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients
Sections
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Is conduct disorder real?

Article Type
Changed
Mon, 04/16/2018 - 14:16
Display Headline
Is conduct disorder real?

I am rebutting “How to reduce aggression in patients with conduct disorder” (Current Psychiatry, April 2004).

A 15-year-old ended his first two visits with me under police custody and was committed both times. After the first commitment, his grandmother filed a petition alleging unruly/delinquent behavior, and a judge ordered the boy to take his prescribed mood stabilizers. That was necessary because the hospital psychiatrist had determined that the boy was not mentally ill and that his grandmother needed parenting classes. The youth’s original diagnosis—conduct disorder and oppositional-defiant disorder (ODD)—contradicted my diagnosis: bipolar disorder, mixed.

During the second hospitalization, a psychiatrist diagnosed the youth as having attentiondeficit/hyperactivity disorder (ADHD). The doctor prescribed methylphenidate and oxcarbazepine, but the patient’s guardian did not consent to the medications.

Facing a sentence at the county juvenile detention center, the youth started taking olanzapine, 10 mg at bedtime, and lamotrigine, 25 mg bid titrated to 50 mg bid, as I had prescribed. His grandmother says that he no longer exhibits defiant behavior. At his third visit, he shook my hand and said, “Thank you for finding the right medications for me.”

I have seen hundreds of similar cases over 10 years. To paraphrase a colleague, diagnosing somebody with conduct disorder or ODD is like diagnosing a patient with a runny nose after a thorough emergency room examination.

I applaud the American Association of Community Psychiatry’s efforts to urge the American Psychiatric Association (APA) to abolish the conduct disorder diagnosis. I also support the many researchers who are requesting elimination of conduct disorder and ODD. These are not real and specific diagnoses but are alleged syndromes that express several conditions.

Manuel Mota-Castillo MD
Orlando, FL

Dr. Malone responds

It is hard to assess Dr. Mota-Castillo’s case based on the information he provided. Still, one would not refute any psychiatric syndrome by citing a single case.

Most psychiatric disorders are syndromes and affect heterogeneous groups. This is true for disorders that are more prevalent in adults—such as schizophrenia and mania—and for those that present in childhood and adolescence—such as conduct disorder, ODD, and ADHD. Heterogeneity within disorders is no doubt related to underlying individual differences in genetics and environment and contributes to differences in symptom expression and treatment response.

Dr. Mota-Castillo did not present symptoms listed under DSM-IV-TR, so it is unclear how the patient was diagnosed. Diagnoses:

  • are one clinician’s impression or the consensus of several clinicians
  • are based on one patient encounter or ongoing treatment
  • occur with or without input from other sources, such as parents and school
  • are made with or without validated structured interviews.

Conduct disorder and ODDare part of DSM diagnostic nomenclature,1 and the APA and American Academy of Child and Adolescent Psychiatry recognize both disorders. Reducing aggression associated with either disorder has long been the most common reason for psychiatric consultation in children.2

Also, Dr. Mota-Castillo prescribed olanzapine and lamotrigine, apparently for simultaneous use. The main point of our case was to discourage polypharmacy—something most experts agree should be avoided3 —by carefully starting one drug before adding a second. When a child receives two drugs at once, we cannot know the effect of either.

In the 15-year-old’s case, as often happens, the prescribed treatment might not have changed the symptoms; some symptoms remit spontaneously.

Nor does drug response clarify diagnosis. For example, both bipolar disorder and aggression in conduct disorder (and in many other conditions) may respond to an antipsychotic.4 Lithium and other treatments for mania have been shown to reduce severe aggression in nonmanic children and adolescents with conduct disorder.5,6

Richard P. Malone, MD
Associate professor
Eastern Pennsylvania Psychiatric Institute
Drexel University College of Medicine
Philadelphia, PA

References

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed-rev). Washington, DC: American Psychiatric Association, 2000.
  2. Kazdin AE. Conduct disorders in childhood and adolescence, vol. 9: developmental clinical psychology and psychiatry series. Newbury Park, CA: Sage Publications, 1987.
  3. Pappadopulos E, Macintyre JC II, Crismon ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY): Part II. J Am Acad Child Adolesc Psychiatry 2003;42(2):145–61.
  4. Malone RP, Delaney MA. Psychopharmacologic interventions in children with aggression: neuroleptics, lithium, and anticonvulsants. In: Coccaro EF (ed). Aggression: assessment and treatment.New York: Marcel Dekker, 2003:331–49.
  5. Malone RP, Delaney MA, Luebbert JF, et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 2000;57(7):649–54.
  6. Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995;34(4):445–53.
Article PDF
Author and Disclosure Information

Issue
Current Psychiatry - 03(08)
Publications
Topics
Page Number
2-10
Sections
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

I am rebutting “How to reduce aggression in patients with conduct disorder” (Current Psychiatry, April 2004).

A 15-year-old ended his first two visits with me under police custody and was committed both times. After the first commitment, his grandmother filed a petition alleging unruly/delinquent behavior, and a judge ordered the boy to take his prescribed mood stabilizers. That was necessary because the hospital psychiatrist had determined that the boy was not mentally ill and that his grandmother needed parenting classes. The youth’s original diagnosis—conduct disorder and oppositional-defiant disorder (ODD)—contradicted my diagnosis: bipolar disorder, mixed.

During the second hospitalization, a psychiatrist diagnosed the youth as having attentiondeficit/hyperactivity disorder (ADHD). The doctor prescribed methylphenidate and oxcarbazepine, but the patient’s guardian did not consent to the medications.

Facing a sentence at the county juvenile detention center, the youth started taking olanzapine, 10 mg at bedtime, and lamotrigine, 25 mg bid titrated to 50 mg bid, as I had prescribed. His grandmother says that he no longer exhibits defiant behavior. At his third visit, he shook my hand and said, “Thank you for finding the right medications for me.”

I have seen hundreds of similar cases over 10 years. To paraphrase a colleague, diagnosing somebody with conduct disorder or ODD is like diagnosing a patient with a runny nose after a thorough emergency room examination.

I applaud the American Association of Community Psychiatry’s efforts to urge the American Psychiatric Association (APA) to abolish the conduct disorder diagnosis. I also support the many researchers who are requesting elimination of conduct disorder and ODD. These are not real and specific diagnoses but are alleged syndromes that express several conditions.

Manuel Mota-Castillo MD
Orlando, FL

Dr. Malone responds

It is hard to assess Dr. Mota-Castillo’s case based on the information he provided. Still, one would not refute any psychiatric syndrome by citing a single case.

Most psychiatric disorders are syndromes and affect heterogeneous groups. This is true for disorders that are more prevalent in adults—such as schizophrenia and mania—and for those that present in childhood and adolescence—such as conduct disorder, ODD, and ADHD. Heterogeneity within disorders is no doubt related to underlying individual differences in genetics and environment and contributes to differences in symptom expression and treatment response.

Dr. Mota-Castillo did not present symptoms listed under DSM-IV-TR, so it is unclear how the patient was diagnosed. Diagnoses:

  • are one clinician’s impression or the consensus of several clinicians
  • are based on one patient encounter or ongoing treatment
  • occur with or without input from other sources, such as parents and school
  • are made with or without validated structured interviews.

Conduct disorder and ODDare part of DSM diagnostic nomenclature,1 and the APA and American Academy of Child and Adolescent Psychiatry recognize both disorders. Reducing aggression associated with either disorder has long been the most common reason for psychiatric consultation in children.2

Also, Dr. Mota-Castillo prescribed olanzapine and lamotrigine, apparently for simultaneous use. The main point of our case was to discourage polypharmacy—something most experts agree should be avoided3 —by carefully starting one drug before adding a second. When a child receives two drugs at once, we cannot know the effect of either.

In the 15-year-old’s case, as often happens, the prescribed treatment might not have changed the symptoms; some symptoms remit spontaneously.

Nor does drug response clarify diagnosis. For example, both bipolar disorder and aggression in conduct disorder (and in many other conditions) may respond to an antipsychotic.4 Lithium and other treatments for mania have been shown to reduce severe aggression in nonmanic children and adolescents with conduct disorder.5,6

Richard P. Malone, MD
Associate professor
Eastern Pennsylvania Psychiatric Institute
Drexel University College of Medicine
Philadelphia, PA

References

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed-rev). Washington, DC: American Psychiatric Association, 2000.
  2. Kazdin AE. Conduct disorders in childhood and adolescence, vol. 9: developmental clinical psychology and psychiatry series. Newbury Park, CA: Sage Publications, 1987.
  3. Pappadopulos E, Macintyre JC II, Crismon ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY): Part II. J Am Acad Child Adolesc Psychiatry 2003;42(2):145–61.
  4. Malone RP, Delaney MA. Psychopharmacologic interventions in children with aggression: neuroleptics, lithium, and anticonvulsants. In: Coccaro EF (ed). Aggression: assessment and treatment.New York: Marcel Dekker, 2003:331–49.
  5. Malone RP, Delaney MA, Luebbert JF, et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 2000;57(7):649–54.
  6. Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995;34(4):445–53.

I am rebutting “How to reduce aggression in patients with conduct disorder” (Current Psychiatry, April 2004).

A 15-year-old ended his first two visits with me under police custody and was committed both times. After the first commitment, his grandmother filed a petition alleging unruly/delinquent behavior, and a judge ordered the boy to take his prescribed mood stabilizers. That was necessary because the hospital psychiatrist had determined that the boy was not mentally ill and that his grandmother needed parenting classes. The youth’s original diagnosis—conduct disorder and oppositional-defiant disorder (ODD)—contradicted my diagnosis: bipolar disorder, mixed.

During the second hospitalization, a psychiatrist diagnosed the youth as having attentiondeficit/hyperactivity disorder (ADHD). The doctor prescribed methylphenidate and oxcarbazepine, but the patient’s guardian did not consent to the medications.

Facing a sentence at the county juvenile detention center, the youth started taking olanzapine, 10 mg at bedtime, and lamotrigine, 25 mg bid titrated to 50 mg bid, as I had prescribed. His grandmother says that he no longer exhibits defiant behavior. At his third visit, he shook my hand and said, “Thank you for finding the right medications for me.”

I have seen hundreds of similar cases over 10 years. To paraphrase a colleague, diagnosing somebody with conduct disorder or ODD is like diagnosing a patient with a runny nose after a thorough emergency room examination.

I applaud the American Association of Community Psychiatry’s efforts to urge the American Psychiatric Association (APA) to abolish the conduct disorder diagnosis. I also support the many researchers who are requesting elimination of conduct disorder and ODD. These are not real and specific diagnoses but are alleged syndromes that express several conditions.

Manuel Mota-Castillo MD
Orlando, FL

Dr. Malone responds

It is hard to assess Dr. Mota-Castillo’s case based on the information he provided. Still, one would not refute any psychiatric syndrome by citing a single case.

Most psychiatric disorders are syndromes and affect heterogeneous groups. This is true for disorders that are more prevalent in adults—such as schizophrenia and mania—and for those that present in childhood and adolescence—such as conduct disorder, ODD, and ADHD. Heterogeneity within disorders is no doubt related to underlying individual differences in genetics and environment and contributes to differences in symptom expression and treatment response.

Dr. Mota-Castillo did not present symptoms listed under DSM-IV-TR, so it is unclear how the patient was diagnosed. Diagnoses:

  • are one clinician’s impression or the consensus of several clinicians
  • are based on one patient encounter or ongoing treatment
  • occur with or without input from other sources, such as parents and school
  • are made with or without validated structured interviews.

Conduct disorder and ODDare part of DSM diagnostic nomenclature,1 and the APA and American Academy of Child and Adolescent Psychiatry recognize both disorders. Reducing aggression associated with either disorder has long been the most common reason for psychiatric consultation in children.2

Also, Dr. Mota-Castillo prescribed olanzapine and lamotrigine, apparently for simultaneous use. The main point of our case was to discourage polypharmacy—something most experts agree should be avoided3 —by carefully starting one drug before adding a second. When a child receives two drugs at once, we cannot know the effect of either.

In the 15-year-old’s case, as often happens, the prescribed treatment might not have changed the symptoms; some symptoms remit spontaneously.

Nor does drug response clarify diagnosis. For example, both bipolar disorder and aggression in conduct disorder (and in many other conditions) may respond to an antipsychotic.4 Lithium and other treatments for mania have been shown to reduce severe aggression in nonmanic children and adolescents with conduct disorder.5,6

Richard P. Malone, MD
Associate professor
Eastern Pennsylvania Psychiatric Institute
Drexel University College of Medicine
Philadelphia, PA

References

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed-rev). Washington, DC: American Psychiatric Association, 2000.
  2. Kazdin AE. Conduct disorders in childhood and adolescence, vol. 9: developmental clinical psychology and psychiatry series. Newbury Park, CA: Sage Publications, 1987.
  3. Pappadopulos E, Macintyre JC II, Crismon ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY): Part II. J Am Acad Child Adolesc Psychiatry 2003;42(2):145–61.
  4. Malone RP, Delaney MA. Psychopharmacologic interventions in children with aggression: neuroleptics, lithium, and anticonvulsants. In: Coccaro EF (ed). Aggression: assessment and treatment.New York: Marcel Dekker, 2003:331–49.
  5. Malone RP, Delaney MA, Luebbert JF, et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 2000;57(7):649–54.
  6. Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995;34(4):445–53.
Issue
Current Psychiatry - 03(08)
Issue
Current Psychiatry - 03(08)
Page Number
2-10
Page Number
2-10
Publications
Publications
Topics
Article Type
Display Headline
Is conduct disorder real?
Display Headline
Is conduct disorder real?
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

The sports physical: One-on-one is OK; one-on-300 is not

Article Type
Changed
Fri, 10/05/2018 - 10:21
Display Headline
The sports physical: One-on-one is OK; one-on-300 is not
Article PDF
Author and Disclosure Information

Douglas S. Moodie, MD, MS
Chairman, Ochsner for Children, Alton Ochsner Foundation, New Orleans, LA

Address: Douglas S. Moodie, MD, MS, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121; e-mail dmoodie@ochsner.org

Issue
Cleveland Clinic Journal of Medicine - 71(7)
Publications
Topics
Page Number
585-586
Sections
Author and Disclosure Information

Douglas S. Moodie, MD, MS
Chairman, Ochsner for Children, Alton Ochsner Foundation, New Orleans, LA

Address: Douglas S. Moodie, MD, MS, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121; e-mail dmoodie@ochsner.org

Author and Disclosure Information

Douglas S. Moodie, MD, MS
Chairman, Ochsner for Children, Alton Ochsner Foundation, New Orleans, LA

Address: Douglas S. Moodie, MD, MS, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121; e-mail dmoodie@ochsner.org

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 71(7)
Issue
Cleveland Clinic Journal of Medicine - 71(7)
Page Number
585-586
Page Number
585-586
Publications
Publications
Topics
Article Type
Display Headline
The sports physical: One-on-one is OK; one-on-300 is not
Display Headline
The sports physical: One-on-one is OK; one-on-300 is not
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

What kind of physical examination does a young athlete need before participating in sports?

Article Type
Changed
Fri, 10/05/2018 - 11:06
Display Headline
What kind of physical examination does a young athlete need before participating in sports?
Article PDF
Author and Disclosure Information

Thomas M. Mick, MD
Section of Sports Medicine, The Cleveland Clinic Foundation

Robert J. Dimeff, MD
Section of Sports Medicine, The Cleveland Clinic Foundation

Address: Robert J. Dimeff, MD, Department of Sports Medicine, A41, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Issue
Cleveland Clinic Journal of Medicine - 71(7)
Publications
Topics
Page Number
587-597
Sections
Author and Disclosure Information

Thomas M. Mick, MD
Section of Sports Medicine, The Cleveland Clinic Foundation

Robert J. Dimeff, MD
Section of Sports Medicine, The Cleveland Clinic Foundation

Address: Robert J. Dimeff, MD, Department of Sports Medicine, A41, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Author and Disclosure Information

Thomas M. Mick, MD
Section of Sports Medicine, The Cleveland Clinic Foundation

Robert J. Dimeff, MD
Section of Sports Medicine, The Cleveland Clinic Foundation

Address: Robert J. Dimeff, MD, Department of Sports Medicine, A41, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 71(7)
Issue
Cleveland Clinic Journal of Medicine - 71(7)
Page Number
587-597
Page Number
587-597
Publications
Publications
Topics
Article Type
Display Headline
What kind of physical examination does a young athlete need before participating in sports?
Display Headline
What kind of physical examination does a young athlete need before participating in sports?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Spinal tuberculosis deserves a place on the radar screen

Article Type
Changed
Fri, 10/05/2018 - 10:25
Display Headline
Spinal tuberculosis deserves a place on the radar screen
Article PDF
Author and Disclosure Information

Robert F. McLain, MD
Director, Spine Research, Department of Orthopaedic Surgery, The Cleveland Clinic Foundation

Carlos Isada, MD
Department of Infectious Disease, The Cleveland Clinic Foundation

Address: Robert F. McLain, MD, Department of Orthopaedic Surgery, A41, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mclainr@ccf.org

Issue
Cleveland Clinic Journal of Medicine - 71(7)
Publications
Topics
Page Number
537-539, 543-549
Sections
Author and Disclosure Information

Robert F. McLain, MD
Director, Spine Research, Department of Orthopaedic Surgery, The Cleveland Clinic Foundation

Carlos Isada, MD
Department of Infectious Disease, The Cleveland Clinic Foundation

Address: Robert F. McLain, MD, Department of Orthopaedic Surgery, A41, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mclainr@ccf.org

Author and Disclosure Information

Robert F. McLain, MD
Director, Spine Research, Department of Orthopaedic Surgery, The Cleveland Clinic Foundation

Carlos Isada, MD
Department of Infectious Disease, The Cleveland Clinic Foundation

Address: Robert F. McLain, MD, Department of Orthopaedic Surgery, A41, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mclainr@ccf.org

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 71(7)
Issue
Cleveland Clinic Journal of Medicine - 71(7)
Page Number
537-539, 543-549
Page Number
537-539, 543-549
Publications
Publications
Topics
Article Type
Display Headline
Spinal tuberculosis deserves a place on the radar screen
Display Headline
Spinal tuberculosis deserves a place on the radar screen
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Coping with the symptoms of menopause

Article Type
Changed
Fri, 10/05/2018 - 10:54
Display Headline
Coping with the symptoms of menopause
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 71(7)
Publications
Topics
Page Number
583-584
Sections
Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 71(7)
Issue
Cleveland Clinic Journal of Medicine - 71(7)
Page Number
583-584
Page Number
583-584
Publications
Publications
Topics
Article Type
Display Headline
Coping with the symptoms of menopause
Display Headline
Coping with the symptoms of menopause
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Biannual HIV Testing for Service Members

Article Type
Changed
Tue, 12/13/2016 - 12:08
Display Headline
Biannual HIV Testing for Service Members

Article PDF
Author and Disclosure Information

Issue
Federal Practitioner - 21(7)
Publications
Topics
Page Number
11
Legacy Keywords
force health protection and readiness, HIV, testingforce health protection and readiness, HIV, testing
Sections
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

Issue
Federal Practitioner - 21(7)
Issue
Federal Practitioner - 21(7)
Page Number
11
Page Number
11
Publications
Publications
Topics
Article Type
Display Headline
Biannual HIV Testing for Service Members
Display Headline
Biannual HIV Testing for Service Members
Legacy Keywords
force health protection and readiness, HIV, testingforce health protection and readiness, HIV, testing
Legacy Keywords
force health protection and readiness, HIV, testingforce health protection and readiness, HIV, testing
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

A Diagnostic Pearl: The School Chair Sign

Article Type
Changed
Tue, 05/07/2019 - 15:00
Display Headline
A Diagnostic Pearl: The School Chair Sign

Article PDF
Author and Disclosure Information

Samimi SS, Siegfried E, Belsito DV

Issue
Cutis - 74(1)
Publications
Topics
Page Number
27-28
Sections
Author and Disclosure Information

Samimi SS, Siegfried E, Belsito DV

Author and Disclosure Information

Samimi SS, Siegfried E, Belsito DV

Article PDF
Article PDF

Issue
Cutis - 74(1)
Issue
Cutis - 74(1)
Page Number
27-28
Page Number
27-28
Publications
Publications
Topics
Article Type
Display Headline
A Diagnostic Pearl: The School Chair Sign
Display Headline
A Diagnostic Pearl: The School Chair Sign
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media